With more than 500 million confirmed cases of COVID-19 and 10% of infected individuals suffering persistent symptoms, patient-reported low health related quality of life has become a vast problem for individuals, health care systems and society for years to come [
1].
Post COVID condition (PCC), also known as Long COVID is commonly defined as having a history of probable or confirmed SARS-CoV-2 infection, and persistent symptoms 3 months from the onset of COVID-19 [
2]. Common symptoms are fatigue, shortness of breath and cognitive dysfunction [
3]. Mechanisms are still an enigma but suggested mechanisms include auto-immune disease such as dysregulated T-cell activation, chronic oxidative stress, mitochondrial dysfunction, and endothelial dysfunction [
4].
No effective evidence-based treatment options for the underlying condition have been widely adopted in clinical practice and many patients seek expensive “remedies” for self-management [
5]. Hyperbaric oxygen (HBO
2) is a possibly effective drug but has not been evaluated for safety and efficacy in compliance with International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use-Good Clinical Practice (ICH-GCP) for PCC in clinical trials. It has been suggested to be effective in similar conditions such as Fibromyalgia and Chronic Fatigue syndrome [
6,
7]. HBO
2 has become increasingly popular off-label, a couple of case reports/series are published and RCTs are on the way [
8‐
10]. Since the first submission of this manuscript one RCT including 73 subjects have shown an improvement of neurocognitive function and symptoms in PCC with 40 sessions of HBO
2 at 2 Bar for 90 min with five-minute air breaks every 20 min [
11]. Our hypothesis for use of HBO
2 in PCC is based on the hyperoxic-hypoxic paradox with activation of Hypoxia Inducible Factor 1 and 2 (HIF-1 and HIF-2) and downstream regulation of hypoxia and inflammatory pathways [
12,
13]. The rationale for using fewer and less frequent sessions is based on the above hypotheses, previous clinical experience and from experimental research including own unpublished data. The safety profile of HBO
2 is well known for accepted indications but has not been described in compliance with ICH-GCP and is not an accepted treatment for patients diagnosed with PCC [
14]. The aim of the interim analysis was to evaluate safety of HBO
2 for our cohort by evaluating reported adverse events (AE) and serious adverse events (SAE) in compliance with ICH-GCP.